Home » Topics » Disease categories and therapies » Urology

Urology
RSS

RU-58642: potent new antiandrogen for androgen-dependent prostate disorders

June 2, 1998

PPD and Lilly join forces to develop genitourinary compounds

May 28, 1998

ETA antagonist has protective effects in hypertensive rat model of renal damage

May 27, 1998

Renal effects of BG-9719 demonstrated in CHF patients and healthy volunteers

May 22, 1998

Profile of eplerenone, a novel aldosterone antagonist from Searle

May 20, 1998

Yamanouchi prepares novel antimuscarinic agents for renal, GI and respiratory disorders

May 11, 1998

Wyeth-Ayerst has option to license Teikoku Hormone's antiandrogen

May 7, 1998

FDA clears CRYOcare surgical system to treat BPH

May 4, 1998

Cheung seeks FDA approval to begin testing of BPH treatment system

April 30, 1998

Takeda presents agents inhibiting PDGF activity for renal, cardiovascular disorders

April 29, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Recludix’s first-in-class STAT6 inhibitor shows efficacy in atopic dermatitis
BioWorld Science
Researchers from Recludix Pharma Inc. reported preclinical efficacy data on REX-8756 (SAR-448755), a first-in-class orthosteric STAT6 inhibitor in models of...